Evogene (NASDAQ:EVGN) & Bolt Biotherapeutics (NASDAQ:BOLT) Critical Analysis

Bolt Biotherapeutics (NASDAQ:BOLT) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Bolt Biotherapeutics and Evogene, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1	1	2	0	2.25
Evogene	1	0	0	0	1.00

Bolt Biotherapeutics currently has a consensus price target of $14.50, indicating a potential upside of 267.09%. Given Bolt Biotherapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Bolt Biotherapeutics is more favorable than Evogene.

Profitability

This table compares Bolt Biotherapeutics and Evogene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%
Evogene	-694.18%	-156.53%	-86.80%

Valuation and Earnings

This table compares Bolt Biotherapeutics and Evogene”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70 million	0.99	-$33.38 million	($16.44)	-0.24
Evogene	$3.85 million	1.09	-$8.48 million	($0.91)	-0.53

Evogene has lower revenue, but higher earnings than Bolt Biotherapeutics. Evogene is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Bolt Biotherapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Institutional and Insider Ownership

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 7.4% of Evogene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Bolt Biotherapeutics beats Evogene on 10 of the 14 factors compared between the two stocks.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.